These results revealed that 6j is a potential drug candidate against MRSA infection, thus providing a reference for the development of anti-MRSA drugs
QUESTION: Because this article talks about derivatives of an antibiotic that makes it harder for bacteria to resist, I would want to know how does the decay rate of this new derivative, more specifically 6j, compare to the decay rate of the original antibiotic. Therefore, would the drug have to be taken more or less frequently for optimum use. Also, if the 6j derivative stays in the blood stream, does the environment the bacteria could potentially create cause reversification back into the original form of the drug or into an ineffective form of the drug?